AM-679, a member of the AM cannabinoid series, is a moderately potent agonist for cannabinoid receptors. It exhibits a Ki of 13.5 nM at CB1 and 49.5 nM at CB2, signifying its affinity for these receptors. Notably, AM-679 was among the pioneering 3-(2-iodobenzoyl)indole derivatives to display a noteworthy affinity for cannabinoid receptors. While AM-679 itself demonstrates only modest receptor affinity, it played a pivotal role as a foundational compound for the development of specialized cannabinoid ligands extensively employed in research. These derivatives include the potent CB1 agonists AM-694 and AM-2233, as well as the selective CB2 agonist AM-1241. Interestingly, AM-679 gained recognition after its identification as a cannabinoid designer drug sold in Hungary in 2011, alongside another novel compound, 1-pentyl-3-(1-adamantyl)indole. This underscores the compound’s presence in the ever-evolving landscape of unknown psychoactive substances.
What is AM-679, and how does it relate to cannabinoids?
AM-679 is a compound belonging to the AM cannabinoid series. It acts as a moderately potent agonist for cannabinoid receptors, with notable affinity for CB1 and CB2 receptors.
What is the Ki value of AM-679 at CB1 and CB2 receptors?
AM-679 has a Ki value of 13.5 nM at CB1 and 49.5 nM at CB2 receptors, indicating its binding affinity for these cannabinoid receptors.
Why is AM-679 significant in cannabinoid research?
AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives with substantial affinity for cannabinoid receptors. It was a foundational compound for developing specialized cannabinoid ligands widely used in research.
Can you provide examples of these specialized cannabinoid ligands developed from AM-679?
Indeed, the development of AM-679 led to the creation of notable compounds like AM-694 and AM-2233, which are potent CB1 agonists, as well as AM-1241, a selective CB2 agonist. These derivatives have played crucial roles in cannabinoid research.
Was AM-679 ever used as a designer drug?
Yes, AM-679 gained attention when it was identified as a cannabinoid designer drug being sold in Hungary in 2011. This underscores its presence in the world of novel psychoactive substances.
What is the significance of the AM cannabinoid series?
The AM cannabinoid series, which includes compounds like AM-679, has been instrumental in advancing our understanding of cannabinoid receptors and their ligands, contributing to research in cannabinoid pharmacology.
Is AM-679 legal for research or recreational use?
The legal status of AM-679 may vary by jurisdiction, but it is typically used for research purposes. Researchers should ensure compliance with local and national regulations when working with such compounds.
Where can I find more information about AM-679 and related research?
To learn more about AM-679 and its applications in cannabinoid research, you can explore scientific journals academic databases, and consult experts in the field of cannabinoid pharmacology. Always adhere to appropriate safety and legal guidelines when researching or handling such substances.
WO patent 200128557, authored by Makriyannis A and Deng H, titled “Cannabimimetic Indole Derivatives,” was granted on June 7, 2001. This patent represents a significant milestone in the field of cannabinoid research, highlighting the development of indole derivatives with cannabimimetic properties.
In 2000, Deng H’s doctoral dissertation at the University of Connecticut, titled “Design and Synthesis of Selective Cannabinoid Receptor Ligands: Aminoalkylindole and Other Heterocyclic Analogs,” contributed to our understanding of selective cannabinoid receptor ligands. This research laid the foundation for the development of novel compounds in the field of cannabinoid pharmacology.
The work of Jankovics P, Váradi A, Tölgyesi L, Lohner S, Németh-Palotás J, and Balla J, published in January 2012 in “Forensic Science International” (214(1–3), 27–32), focused on the detection and identification of new potential synthetic cannabinoids. They investigated compounds, including 1-pentyl-3-(2-iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole, in seized bulk powders in Hungary, shedding light on emerging substances in the realm of synthetic cannabinoids.